What Dalatina Treats: Main Uses and Benefits

Dalatina is used in clinical settings that involve acute or disruptive symptom patterns primarily caused by certain types of susceptible bacteria. The medication is applied across domains where additional symptomatic support is needed for conditions like serious systemic infections, bone and joint infections, and infections of the respiratory and female reproductive tracts.

The medication helps address symptom clusters that may become intense or disruptive, such as high fever, deep-seated inflammation, and the painful swelling associated with severe skin and soft tissue infections (e.g., cellulitis and abscesses). It is relevant when supportive symptom management is appropriate, especially for penicillin-allergic patients requiring effective therapeutic alternatives.

“Dalatina helps ease the overall symptom burden and supports patient stability during difficult infectious episodes.”

In these scenarios, the medication contributes to improved day-to-day comfort, assisting with maintaining functional stability and easing distress when symptoms interfere with routine activities.

---

Quick Fact: Symptom Management Overview

Use Context	Symptoms Targeted	Patient Benefit
Deep-Seated Infections	Systemic imbalance, fever, spreading inflammation	Supports comfort during symptomatic phases
Skin Conditions	Painful swelling, inflammatory lesions, tenderness	Contributes to easing the overall symptom load
Allergy Alternative	Symptoms related to acute or episodic changes	Supports the patient when alternatives are needed

Who Can and Cannot Use Dalatina?

Eligibility Status	Official Regulatory Rules
Contraindicated Populations	Individuals with a history of hypersensitivity to Dalatina (Clindamycin) or Lincomycin. Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis may be prohibited from use.
Non-Eligibility	The medicine should not be used to treat nonbacterial infections or meningitis, as it does not adequately diffuse into the cerebrospinal fluid.

Population-Specific Requirements

• Age Groups: Dalatina is approved for adults and the pediatric population, including neonates, though infants under one month require close organ function monitoring. Older patients with normal organ function do not require dosage alteration based on age alone.
• Pregnancy/Lactation: Use during the first trimester of pregnancy is restricted to situations where it is clearly necessary. It is generally not recommended for nursing mothers due to the potential for infant gastrointestinal effects.
• Organ Function: No standard dosage adjustment is necessary for patients with renal or hepatic impairment; however, severe cases require periodic monitoring of liver or kidney function.
• Conditional Use: Caution is required for patients with a history of gastrointestinal disease, atopic individuals, or those taking other neuromuscular blocking agents.

The official regulatory profile restricts Dalatina's use primarily to penicillin-allergic patients or those for whom less toxic agents are unsuitable, while mandating absolute exclusion for hypersensitivity and imposing conditional use constraints for populations with GI history or severe organ impairment.

Interactions with other medicines and products

Regulatory documentation defines specific patterns and restrictions for the co-administration of Dalatina (Clindamycin) with other medicines and products.

Documented Interaction Patterns

The co-administration of Dalatina with certain other antibacterials, such as Macrolides (e.g., Erythromycin), is officially prohibited due to evidence of antibacterial antagonism. Anti-peristaltic medicines, like Opiates, are conditionally contraindicated if antibiotic-associated colitis is suspected or confirmed, as they may prolong the condition.

Dalatina is metabolized by CYP3A4 and CYP3A5 enzymes. Strong enzyme inducers (e.g., Rifampicin) may increase Dalatina clearance, potentially reducing its systemic exposure. Conversely, CYP inhibitors may reduce clearance, leading to increased plasma concentrations of Dalatina.

Pharmacodynamic and Procedural Constraints

Clindamycin has intrinsic neuromuscular blocking properties that can enhance the action of other Neuromuscular Blocking Agents. Additionally, co-use with Vitamin K Antagonists (e.g., Warfarin) has been reported to cause increased INR/PT values, requiring frequent monitoring of coagulation tests.

In terms of timing, the live oral Typhoid Vaccine should be avoided for three days before and after Dalatina administration. Official labels state that the oral absorption of Dalatina is not appreciably affected by food.

Dalatina's mechanism of action is selective, directed at the core machinery involved in bacterial protein synthesis and replication. The drug operates through two primary mechanistic domains: Inhibition of Microbial Protein Synthesis and Modulation of Virulence Factor Production.

Inhibition of Microbial Protein Synthesis

The active molecule binds specifically to the 50S ribosomal subunit of the bacterial 70S ribosome, which is required for manufacturing proteins. By docking near the Peptidyl Transferase Center, the molecule physically arrests peptide chain elongation and the synthesis of structural and enzymatic proteins. This specific molecular event results in a bacteriostatic effect that halts microbial multiplication.

Modulation of Pathogen Virulence

This secondary mechanism extends to the regulation of bacterial pathogenicity. Clindamycin influences pathways responsible for the production and secretion of specific virulence factors, such as exotoxins. By reducing the synthesis of these damaging products, the mechanism is associated with a reduction in local inflammatory mediators and causes a decrease in the systemic concentration of bacterial toxins, which supports the physiological process of microbial clearance by the host immune system.

Official Administration Guidelines

Dalatina (Clindamycin) is administered through several approved systemic routes: oral (capsule or solution), intravenous (IV) infusion, and intramuscular (IM) injection. The medication is used at consistent, scheduled intervals to maintain drug concentrations required for its intended effect.

Dosing and Frequency

Official dosing is based on the severity of the clinical scenario and the route selected:

Route	Typical Adult Dosing Range	Dosing Frequency
Oral (Capsule)	150 mg to 450 mg	Every 6 hours
IV/IM	600 mg to 2700 mg per day	Divided into 2, 3, or 4 equal doses

The maximum recommended intravenous dose for adults in severe situations is up to 4800 mg per day. For beta-hemolytic streptococcal infections, the official course of therapy must be maintained for a minimum of ten days.

Administration Instructions

Oral Use: Capsules must be swallowed whole with a full glass of water to avoid irritation to the esophagus. Administration may occur without regard to food.

IV/IM Use: The injectable solution must be diluted prior to intravenous administration, and the infusion rate is controlled to not exceed 30 mg per minute. A single intramuscular injection is generally limited to 600 mg per site.

Population Principles: No dose adjustment is required for older adults based on age alone, nor is adjustment typically necessary for patients with non-severe renal or hepatic impairment when the medication is administered every eight hours. Pediatric dosing is calculated based on body weight or body surface area.

Research evidence / Overview of Studies for Dalatina (Clindamycin)

This section provides an overview of the official research evidence for Dalatina, describing the types of studies conducted and what findings were observed by researchers, without offering clinical advice or interpretations.

---

Evidence for use in Serious Systemic Infections

Research exploring Dalatina's use in serious systemic infections, such as deep-seated infections of the abdomen, pelvis, or joints, primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews or meta-analyses. These studies monitor outcomes related to physical discomfort and systemic or functional imbalance. Studies examined how outcomes evolved in the observed populations, with measured endpoints including the patient’s rate of clinical resolution and longer-term survival measurements. Findings describe patterns observed in the studies related to measured clinical patterns.

What remains uncertain is the full characterization of long-term outcomes, as follow-up durations were limited in many primary RCTs. Comparative evidence is sometimes lacking for specific adjunctive roles, and evidence highlights that the research needs to continuously address the potential for bacterial resistance over time, a pattern observed in some studies.

Evidence for use in Skin and Soft Tissue Infections

The research base for Dalatina in managing skin and soft tissue infections (SSTIs) is built upon RCTs and observational cohort studies. Research monitored outcomes related to inflammatory or irritative states and the patient's recovery of daily functioning or activity level. Studies compared the patterns measured during the study period when Dalatina was used versus when an alternative treatment was administered. Research has explored short-term symptom changes, and findings describe the measured rates of short-term clinical resolution. Some data show patterns related to measured short-term clinical resolution compared to other agents.

Evidence for use in Localized Inflammatory Skin Conditions

Research for the topical forms of Dalatina, primarily for conditions like acne vulgaris, relies on a foundation of Randomized, Double-Blind, Placebo-Controlled Trials. The primary focus of these studies was to monitor outcomes linked to inflammatory or irritative states on the skin. Studies monitored changes measured during the study period using objective tools like the Evaluator's Global Severity Score (EGSS) and quantified the change in inflammatory lesion counts. Findings describe patterns of difference observed in these studies where certain Dalatina formulations, especially in combinations, were compared against a placebo in terms of lesion counts. Research highlights that the use of topical Dalatina as a single agent was observed in some studies to correlate with the emergence of bacterial resistance.

Evidence in Special Populations

Dalatina has been evaluated in various special populations as part of its clinical program. The research has examined both children and adults in studies for systemic infections and included adolescents in trials for inflammatory skin conditions. Evidence also specifically explored its use in patients with known penicillin allergies who were evaluated for an antibacterial alternative. Furthermore, controlled trials have been conducted for pregnant women during the second and third trimesters of pregnancy for specific infections. However, the sample sizes were modest in some of these subgroup analyses, and the results apply only to the populations studied.

Key Studies & References

1. Topical clindamycin combined with benzoyl peroxide for acne vulgaris: a review of the evidence (Focus on comparative lesion counts and EGSS)

Common questions about Dalatina (FAQ)

---

Q: What is the main medical condition Dalatina is approved to treat?

Dalatina is an antibacterial medicine approved by regulatory agencies for the treatment of specific, serious bacterial infections. This includes deep-seated infections of the respiratory tract, skin and soft tissue, certain infections of the female pelvis and genital tract, and intra-abdominal infections.

---

Q: What is the general therapeutic class of Dalatina?

According to official prescribing information, Dalatina belongs to a class of antibiotics known as Lincosamides. This classification is based on its structure and its specific mechanism of action against bacterial cells.

---

Q: Does Dalatina carry any official 'Black Box' or major warnings from regulatory bodies?

Yes, the official regulatory labeling includes a Boxed Warning. This is a prominent alert regarding the risk of severe diarrhea and inflammation of the colon caused by the C. difficile bacteria (CDAD), which has been reported as potentially fatal.

---

Q: What is stated in official documents about using Dalatina while breastfeeding?

Official documents indicate that Dalatina is excreted into breast milk. Official documents advise that the infant should be monitored for potential changes to their gastrointestinal flora, such as developing diarrhea or oral candidiasis (thrush).

---

Q: What is the half-life of Dalatina according to pharmacokinetics research?

Pharmacokinetic research indicates that the average biological half-life of Dalatina in adults with normal kidney and liver function is approximately two to three hours. This time frame describes how quickly the amount of medicine in the body reduces by half.

---

Q: Does Dalatina affect a person's ability to operate machinery or drive?

Official regulatory documentation states that formal studies to establish the effects of Dalatina on the ability to drive or operate machinery have not been conducted.

---

Q: Does the drug product Dalatina contain any common allergens, such as lactose or gluten?

Official information on inactive ingredients indicates that the oral capsules of Dalatina contain lactose. Regulatory documents do not typically specify the presence or absence of gluten.

---

Q: What were the main findings of the clinical trials for Dalatina?

Clinical studies reviewed by regulatory bodies support the conclusion of effectiveness for the specific, approved bacterial infections. This evidence includes its use in conditions like septicemia, intra-abdominal infections, and severe skin and soft tissue infections.

---

Q: What does official data suggest about the safety of Dalatina in pregnant patients?

Official data suggests that the use of Dalatina during the second and third trimesters of pregnancy was not associated with an increased frequency of congenital abnormalities. Official guidance indicates that use during the first trimester is generally reserved for situations when it is clearly needed. The FDA classification for this drug is Pregnancy Category B.

---

Q: How quickly can a person expect Dalatina to start having an effect?

While the onset of the clinical effect can vary, pharmacokinetic data shows how the drug is absorbed. The highest concentration of the drug in the bloodstream (peak serum level) is typically reached within 45 to 60 minutes after taking an oral dose.

---

Q: Is Dalatina safe to take with alcohol?

Official drug labels do not contain a formal contraindication against mixing Dalatina with alcohol. However, since the drug commonly causes gastrointestinal side effects, consuming alcohol may increase the chance of experiencing nausea or diarrhea.

---

Q: Is it normal to experience dizziness when first starting Dalatina?

Dizziness is listed in regulatory documents as a possible adverse reaction. Official reports indicate that its frequency is described as less common across various formulations of the medicine.

---

Q: Is it common for Dalatina to cause a feeling of drowsiness or fatigue?

While severe drowsiness is not listed among the most common adverse reactions, general fatigue or unusual tiredness has been documented in post-marketing reports. The exact incidence rate of fatigue has not been formally established in the primary clinical trials.

---

Q: What are the main criteria that regulatory agencies use for patient eligibility for Dalatina?

Regulatory documents define eligibility based on the condition being treated and the patient’s medical history. The medicine is strictly contraindicated for patients with a known hypersensitivity to clindamycin or lincomycin. The prescribing information includes warnings and precautions for patients with a history of gastrointestinal diseases, asthma, or severe liver or kidney problems.

---

Q: What are the common signs of an allergic reaction to Dalatina?

Common skin reactions documented include maculopapular rash, urticaria (hives), and pruritus (itching). The official label specifies that severe symptoms, such as swelling of the face or throat and difficulty breathing, are signs that require prompt medical evaluation.

---

Q: Are there specific symptoms that signal a need to seek immediate medical attention while on Dalatina?

Official warnings highlight certain severe symptoms that should prompt urgent consultation. These include signs of a severe allergic reaction, such as difficulty breathing or swelling of the face. Severe, persistent diarrhea is also a critical symptom noted in the Boxed Warning, as it may signal C. difficile-associated diarrhea (CDAD).

Dalatina must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

• Storage Temperature: Store Dalatina at controlled room temperature, which is 20 C to 25 C (68 F to 77 F), with temporary fluctuations permitted between 15 C and 30 C (59 F and 86 F).
• Handling and Protection: Keep the medicine in its original container, and ensure the bottle is tightly closed. It is mandatory to protect the product from freezing.
• Child Safety: To prevent accidental ingestion, Dalatina must be kept out of the sight and reach of children and pets.
• Disposal: The preferred method for disposal of unused or expired Dalatina is a drug take-back program. If a take-back program is not available, the medicine should be mixed with an unappealing substance, such as dirt or used coffee grounds, placed in a sealed bag, and discarded in the household trash. Do not flush this medicine down the toilet unless explicitly instructed by official labeling.